Advertisement

BET inhibition blunts antibody production and macrophage-mediated fibrosis to restore lung function in murine cGVHD
Posted: 06/16/2026 | By: OncGenius Staff

This report investigates how bromodomain and extraterminal (BET) inhibition via OPN-51107 effectively alleviates bronchiolitis obliterans syndrome in murine chronic graft-vs.-host disease. By targeting the CXCL13:CXCR5 axis, treatment blunts pathogenic antibody production and selectively depletes profibrotic M2 macrophages. These combined actions significantly reduce lung collagen deposition and restore pulmonary function, identifying BET proteins as vital therapeutic targets for refractory clinical complications.

Read more on Blood

Question 1 of 5

Despite the recent expansion of the therapeutic arsenal for chronic graft-vs.-host disease (cGVHD), why is bronchiolitis obliterans syndrome (BOS) still considered a critical clinical challenge?

Choose 1

A
First-line corticosteroid therapy has a near-universal 90% response rate, making second-line research redundant
B
Pulmonary cGVHD is purely an inflammatory condition with no fibrotic component, rendering anti-fibrotic agents ineffective
C
BOS is a self-limiting condition that typically resolves without pharmacological intervention within five years post-transplant
D
Approved second-line therapies like ruxolitinib and belumosudil show high efficacy in mild-to-moderate disease but have demonstrated no efficacy for patients with severe BOS

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage